2025-03-01 · medications, prescription, glp-1, phentermine, qsymia, contrave, orlistat, weight-management

Updated 2026-08-07

What's the most effective FDA-approved weight loss medication in 2026?

By average total-body weight loss in pivotal trials, tirzepatide (Zepbound) leads at roughly 20–22% at 72 weeks in SURMOUNT-1, followed by semaglutide 2.4 mg (Wegovy) at about 15% at 68 weeks in STEP-1. Phentermine-topiramate (Qsymia) reaches around 10%, while phentermine, Contrave, and orlistat cluster near 5–7%. Real-world results run 3–5 points lower because of adherence and dose escalation gaps.

How much do prescription weight loss medications actually cost?

Cash retail in 2026: Wegovy and Saxenda list near $1,349 per month, Zepbound near $1,060 with a $349–$499 vial route via LillyDirect, Qsymia around $200–$250, Contrave around $100–$200, and generic phentermine $10–$30. Orlistat is $50 OTC (Alli) to $150 generic. With insurance the picture varies wildly — commercial coverage of GLP-1s for obesity remains near 30–50% of plans and often requires step therapy.

Do I need to be diabetic to get a prescription for tirzepatide or semaglutide?

No. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related condition such as hypertension, dyslipidemia, sleep apnea, or prediabetes. Ozempic and Mounjaro contain the same molecules but are approved for type 2 diabetes; using them off-label for weight loss depends on the prescriber and often on payer rules.

How long do I have to take a weight-loss medication?

Current guidelines from the AACE (2023) and Endocrine Society treat obesity as a chronic disease and expect indefinite therapy for people who respond well and tolerate the drug — much like blood-pressure or lipid-lowering treatment. Short trials of 12–16 weeks are used to confirm at least ~5% loss; if that threshold is missed the drug is typically stopped or switched rather than continued at a higher dose.

What happens if I stop taking the medication?

Most people regain a large share of the weight they lost. In the STEP-1 extension, participants regained about two-thirds of their weight in the year after semaglutide was withdrawn, and cardiometabolic gains reversed alongside it. Tapering, continued lifestyle support, and — for many — a step-down maintenance dose or a switch to a lower-cost agent reduce rebound compared with abrupt discontinuation.

Which weight-loss medication is safest for someone with high blood pressure?

GLP-1 agonists (semaglutide, tirzepatide, liraglutide) usually lower blood pressure by a few mmHg and are the preferred option in controlled hypertension. Orlistat is neutral. Phentermine and phentermine-topiramate (Qsymia) raise heart rate and BP and are avoided in uncontrolled hypertension or established cardiovascular disease. Contrave has a smaller pressor effect but still needs monitoring and is contraindicated when BP is uncontrolled.

Is compounded semaglutide the same as brand-name Wegovy?

No. Compounded semaglutide is not FDA-approved. The FDA lifted the semaglutide (2025) and tirzepatide (2024) shortage designations, removing the legal basis most large-scale compounders were using. Sterility, dose accuracy, and salt-form errors have driven a rise in adverse-event reports. Brand-name FDA-approved products remain the safer baseline whenever access allows.

Can I get a prescription through telehealth?

Yes for most oral agents and, in many states, for injectable GLP-1s from licensed telehealth clinics that require baseline labs, a physician review, and ongoing monitoring. Legitimacy signals to look for: an unrestricted state license for the prescriber, dispensing from an FDA-registered pharmacy, and no pressure to buy compounded product as a first line. Med-spa-style prescribing without lab review is a red flag.

Which prescription weight-loss medication is cheapest in 2026?

Generic phentermine remains the cheapest FDA-approved anti-obesity medication at roughly $10–$30 per month, cash. Generic orlistat runs $50 OTC (Alli) or about $150 as generic Xenical. Contrave brand pricing sits near $100–$200, with clinicians sometimes prescribing separate generic bupropion SR + naltrexone tablets at a lower cost off-label. Qsymia trails at roughly $200–$250. GLP-1s are the most expensive: Zepbound single-dose vials via LillyDirect at $349–$499 are the lowest self-pay route to a GIP/GLP-1 co-agonist, and NovoCare's $225-per-month Wegovy is limited to eligible commercially insured patients.

How long can I stay on a GLP-1 medication?

Indefinitely, if the drug is working, tolerated, and covered. The 2023 AACE guideline and the 2025 Endocrine Society clinical practice guideline both frame obesity as a chronic disease and expect long-term therapy, mirroring how blood pressure and lipid medications are used. In the STEP-4 extension, participants who stayed on semaglutide beyond 20 weeks continued to lose weight and preserved cardiometabolic gains; those who switched to placebo regained weight. The 12-week responder check (≥5% total body-weight loss on max tolerated dose) is a decision point about whether to continue, not a stop date.

Do I need prior authorization for tirzepatide?

Almost always. As of 2026 the great majority of commercial plans that cover Zepbound require prior authorization documenting a BMI ≥30 (or ≥27 with a listed weight-related comorbidity), a documented lifestyle-intervention attempt, and, in step-therapy plans, a prior trial of a lower-cost agent such as phentermine, Contrave, or metformin. Medicare Part D does not cover Zepbound for obesity in 2026 outside a diabetes or cardiovascular indication. Ask the prescribing clinic to run a benefits check before the visit ends — many can pull PA criteria and pre-empt denials.

Prescription Weight Loss Medications

Prescription weight loss medications now range from a 1959-approved oral stimulant to weekly incretin injectables that can produce more than 20% average weight loss. The list of FDA-approved options for chronic weight management is short — seven drugs across five classes — but the choice between them depends on more than efficacy: cost, insurance, side-effect tolerance, medical history, delivery preference, and long-term commitment all matter. This hub compares the current options head to head, explains how prescribers actually pick between them, and walks through the 2026 cost and coverage landscape.

Who this is for / not for

Good fit if:

• You meet BMI criteria (≥30, or ≥27 with a weight-related condition) and want medication support alongside lifestyle changes.
• You want to compare all currently approved options — GLP-1s, phentermine, Qsymia, Contrave, orlistat, Imcivree — on efficacy, cost, and safety in one place.
• You are willing to work with a clinician on baseline labs, monitoring, and a 12-week response check.

Not a fit if:

• You are pregnant, breastfeeding, or planning pregnancy within two months — every approved anti-obesity drug is contraindicated.
• You want a short-term cosmetic loss rather than long-term management of obesity as a chronic disease.
• You want medication without ongoing labs, blood-pressure checks, or lifestyle change.

Quick stats

• Typical weight loss by class (pivotal-trial averages): GLP-1/GIP tirzepatide ~20–22%, GLP-1 semaglutide 2.4 mg ~15%, phentermine-topiramate ~10%, phentermine monotherapy ~6–7%, Contrave ~6%, orlistat ~3–5% at one year.
• Share of anti-obesity prescriptions written by primary care in 2025: roughly 70% (IQVIA prescription-audit data), with endocrinology and obesity medicine writing the balance.
• Average time to weight-loss plateau on GLP-1 therapy: approximately 60–68 weeks (STEP-1 and SURMOUNT-1 curves).
• Commercial insurance coverage of GLP-1s for obesity in 2026: approximately 30–50% of plans, with prior authorization and documented lifestyle-first attempts commonly required.
• Step-therapy prevalence: the majority of covered plans still require a trial of a lower-cost agent (phentermine, Contrave, or orlistat) before approving a GLP-1 for obesity.

Which medications are FDA-approved for weight loss in 2026

The list below covers medications approved specifically for chronic weight management. Drugs sometimes prescribed off-label for weight loss (metformin, SGLT2 inhibitors like empagliflozin, or GLP-1s prescribed under a type 2 diabetes indication such as Ozempic and Mounjaro) are noted separately.

GLP-1 receptor agonists

• Semaglutide 2.4 mg (Wegovy) — weekly subcutaneous injection. Approved 2021 for chronic weight management.
• Liraglutide 3.0 mg (Saxenda) — daily subcutaneous injection. Approved 2014, now off-patent with authorized generics.
• Saxenda vs Wegovy — same manufacturer, different molecule and cadence. Both are Novo Nordisk GLP-1s FDA-approved for obesity, but the STEP-8 head-to-head (Rubino 2022, JAMA) showed semaglutide 2.4 mg delivered −15.8% vs −6.4% on liraglutide at 68 weeks — roughly 2.5x more loss on the newer weekly molecule. Saxenda is now off-patent (FDA-approved generic liraglutide 3.0 mg from Teva in August 2024) and remains a rational choice under step therapy, for patients who prefer daily dosing, or where generic cash-pay beats branded Wegovy. See Saxenda vs Wegovy for the full daily-vs-weekly walkthrough.

GIP + GLP-1 co-agonist

• Tirzepatide (Zepbound) — weekly subcutaneous injection. Approved November 2023 for chronic weight management (SURMOUNT program). Same molecule as Mounjaro (the T2D-label brand); the choice between the two is driven by insurance coverage and the LillyDirect cash-pay vial route, walked through in Mounjaro vs Zepbound. See our head-to-head on semaglutide vs tirzepatide for the trial-vs-trial comparison.

Sympathomimetic stimulants

• Phentermine (Adipex-P, Lomaira) — daily oral. Approved 1959 for short-term use; state-by-state variation on duration.
• Phentermine-topiramate ER (Qsymia) — daily oral. Approved 2012 for chronic use; REMS for teratogenicity.

Opioid antagonist + antidepressant combination

• Bupropion-naltrexone SR (Contrave) — twice-daily oral. Approved 2014.

Lipase inhibitor

• Orlistat (Xenical Rx / Alli OTC) — thrice-daily oral with meals. Rx approved 1999; OTC 2007.

MC4R agonist (rare genetic obesity only)

• Setmelanotide (Imcivree) — daily subcutaneous. Approved 2020 and expanded 2022 for POMC, PCSK1, LEPR, and Bardet-Biedl syndrome. Not for common polygenic obesity.

Off-label mentions. Metformin can produce ~2–3% weight loss and is used adjunctively but has no obesity indication. SGLT2 inhibitors (empagliflozin, dapagliflozin) produce ~1–3% and are indicated for diabetes or heart failure, not weight loss. Ozempic (semaglutide 0.5–2 mg) and Mounjaro (tirzepatide up to 15 mg) share molecules with Wegovy and Zepbound but hold only type 2 diabetes approvals — using them for weight loss without diabetes is off-label and increasingly restricted by payers.

Head-to-head comparison table

Setmelanotide (Imcivree) sits outside this table because it treats only rare monogenic obesity (POMC, PCSK1, LEPR, Bardet-Biedl). Reported average loss in IMCIVREE-201 was ~12% in POMC-deficient adults at one year; cash cost exceeds $18,000 per month and is only sensible under manufacturer patient-assistance or specialty payer coverage.

How prescribers actually choose

Selection is rarely “which drug loses the most weight.” It is a filter: eligibility, then contraindications, then payer, then patient preference.

• BMI eligibility. All FDA-approved anti-obesity drugs require BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, prediabetes, established cardiovascular disease). Setmelanotide requires a confirmed genetic diagnosis instead of a BMI threshold.
• First line for most eligible adults in 2026. A GLP-1 or GIP/GLP-1 agonist is preferred when access exists. Tirzepatide has the largest average loss; semaglutide has the longer post-marketing record. Choice between the two is often driven by insurance formulary and manufacturer savings program eligibility — see the insurance coverage and cost breakdown for how coverage tiers usually play out.
• When phentermine is preferred over a GLP-1. Cost-constrained adults with a normal cardiovascular baseline, no history of substance misuse, and a short-term motivation window (jump-start, event-oriented loss) may do well on generic phentermine, often at $10–$30 per month. State rules on duration vary.
• When Qsymia is preferred over a GLP-1. Adults who cannot tolerate injections, cannot get GLP-1 coverage, and have no glaucoma, pregnancy potential without contraception, or hyperthyroidism can reach nearly double-digit weight loss on oral therapy.
• When Contrave is preferred. Hedonic or reward-driven eating patterns, particularly when appetite is not the dominant problem, sometimes respond better to the naltrexone-bupropion mechanism than to appetite suppressants. For the head-to-head against the other two non-GLP-1 orals — efficacy, cost, safety, and mechanistic fit — see Contrave vs Qsymia vs Phentermine.
• When orlistat is preferred. For adults who cannot use systemic agents (severe uncontrolled psychiatric disease with polypharmacy, some transplant patients) orlistat remains a legitimate, if modest, option — provided vitamin repletion and GI expectations are set clearly.
• The setmelanotide niche. Only after a genetic panel confirms POMC, PCSK1, LEPR, or Bardet-Biedl syndrome does setmelanotide enter the conversation. It is exceptionally effective in that population and not indicated for anyone else.

Insurance coverage and cost

The 2026 coverage picture for anti-obesity medications remains uneven and is the single largest determinant of what most adults can actually take.

• Commercial coverage of GLP-1s for obesity. Roughly 30–50% of employer plans cover Wegovy or Zepbound for chronic weight management as of mid-2026, most with prior authorization, BMI documentation, and a documented lifestyle attempt. Some large plans have carved out weight-loss GLP-1s entirely.
• Medicare Part D. The historical statutory exclusion of anti-obesity drugs from Part D coverage still holds in 2026, with narrow exceptions when a GLP-1 is prescribed under a diabetes or cardiovascular indication (Wegovy carries an approval to reduce major adverse cardiovascular events in adults with established CVD and overweight/obesity). Legislative efforts to close the exclusion have not passed.
• Cash-pay routes. Eli Lilly’s LillyDirect ships tirzepatide as single-dose vials at approximately $349 (2.5 mg starter) to $499 (5 mg and higher), materially below pen pricing. NovoCare offers eligible commercially insured patients Wegovy as low as $225 per month; cash pricing without coverage remains at list. GoodRx and similar discount cards produce meaningful savings on generic phentermine and generic authorized-Saxenda but rarely change GLP-1 pricing in a decisive way.
• Compounded drug pricing. After the FDA lifted the semaglutide (2025) and tirzepatide (2024) shortage designations, the legal basis for large-scale 503A compounding is gone. Compounded prices remain lower than brand ($150–$400 per month is typical) but come with sterility, salt-form, and dose-accuracy concerns; the compounded semaglutide and tirzepatide safety guide walks through what changed and what to ask before starting.

Cheaper oral options (generic phentermine, generic Contrave-equivalent bupropion + naltrexone tablets separately, generic orlistat, Alli OTC) remain widely available and often affordable without insurance.

Efficacy vs adherence — the real-world gap

Pivotal-trial averages assume near-perfect adherence and titration to the target dose. Real-world data are more modest.

• Real-world weight loss. The Watanabe 2024 US claims-data analysis of GLP-1 initiators for obesity showed mean loss of roughly 10.4% at 12 months — a 3–5-point gap versus STEP-1’s ~15% at 68 weeks — driven mostly by dose escalation stopping short of the target and by discontinuation.
• Persistence. Roughly 30–50% of adults starting a GLP-1 for obesity remain on therapy at 12 months in commercial-claims databases. Persistence is higher when access is stable and lower when cost, prior authorization, or supply disruptions intervene.
• GI-driven discontinuation. Roughly 6–8% of semaglutide and tirzepatide users discontinue for GI intolerance in pivotal trials; real-world discontinuation is higher because slower community titration and coaching are less consistent than trial protocols.
• Rebound. In the STEP-1 extension, participants regained approximately two-thirds of lost weight in the year after semaglutide was stopped, and cardiometabolic improvements largely reversed with the weight. That pattern is why current guidelines treat these drugs as chronic therapies rather than short-term interventions — see our detailed look at rebound weight gain after stopping GLP-1s for what the taper conversation looks like.

How the 2026 prescription pipeline compares — five approved drugs, three near-term arrivals

The 2026 shortlist is short, but three phase-3 programs are close enough to launch to change first-line thinking. The table below sets the five current FDA-approved anti-obesity drugs against the three late-stage candidates most likely to reach approval next. Trial averages are from the highest-dose arm and target adults with obesity (or overweight with comorbidity) unless noted; list prices are 2026 US cash retail.

Read the pipeline honestly. Retatrutide phase-2 numbers are best in class today, but phase-3 confirmation, tolerability at the top dose, and payer response are all unresolved. Orforglipron is the first serious oral GLP-1 without an absorption enhancer; if approved, it changes access (no pens, no injections, straightforward cold-chain-free distribution). CagriSema’s phase-3 topline was a step below its own phase-2 curve, and the launch calculus depends on how it is positioned against tirzepatide and retatrutide. For a deeper look at each candidate, see next-generation weight loss drugs; for the current head-to-heads that most patients actually choose between, see semaglutide vs tirzepatide and GLP-1 medications compared.

What the pipeline does not change (yet). Payer coverage lags approval, often by 12–24 months for a new obesity drug.

• Zepbound’s 2023 approval did not translate into broad commercial coverage until mid-2024, and Medicare Part D coverage still requires a cardiovascular or diabetes carve-out.
• The practical access date for a phase-3 candidate is typically the year after approval, not the topline-data date. That gap matters for anyone reading the pipeline as a reason to delay starting a currently-approved therapy.
• First-line choice today is still semaglutide, tirzepatide, or (for cost-constrained access) phentermine-topiramate. Switching to a next-generation drug is a specific decision at a specific plateau, not a wait-and-see.
• Compounded is not a substitute. After the FDA lifted the semaglutide (2025) and tirzepatide (2024) shortage designations, the legal basis for large-scale 503A compounding is gone; compounded product remains cheaper but carries sterility, salt-form, and dose-accuracy risks and is not an equivalent to brand.

Why phase-3 topline is not phase-3 approval. Between topline read-out and FDA approval, phase-3 candidates still have to file a New Drug Application, complete an FDA advisory committee review (usually), publish full efficacy and safety data, and — for GLP-1-class drugs — clear the boxed-warning language on medullary thyroid carcinoma risk. The typical window is 12–18 months from topline to launch, and any signal that turns up in the full data (hepatic aminotransferase elevations, tachycardia, or an unexpected event in the extension arm) can extend it further. Treat phase-3 topline announcements as directional, not decisive.

How maintenance data change the switching calculus. The SURMOUNT-4 maintenance trial (Aronne, JAMA, 2024) demonstrated that adults who continued tirzepatide after a 36-week lead-in kept losing weight through week 88, while those switched to placebo regained roughly half of what they had lost within a year. The parallel STEP-4 maintenance data on semaglutide (Rubino, JAMA, 2021) show the same pattern. What this changes about the current 5-drug list is that the maintenance question — “will the plan cover this indefinitely?” — is now as clinically important as the induction efficacy question. A drug that produces 22% at 72 weeks but loses coverage at week 90 is functionally a 10% drug once the rebound arm is accounted for.

Trial-to-launch translation for each 2026 candidate.

• Retatrutide — phase 2 (Jastreboff, NEJM, 2023): ~24.2% at 48 weeks in the 12 mg arm — the highest magnitude ever reported in a Phase 2 obesity trial. Phase 3 TRIUMPH-1 obesity readout expected late 2026; TRIUMPH-2 (T2D), TRIUMPH-3 (CVD MACE), TRIUMPH-4 (adolescents), and TRIUMPH-5 (knee osteoarthritis) are running. GI-event rate at the top dose and long-term hepatic and glycemic safety from the glucagon arm are the questions the FDA will focus on. See the dedicated retatrutide page for the full trial breakdown and the 2026 gray-market safety picture.
• Orforglipron — phase 2 (Wharton, NEJM, 2023): ~14.7% at 36 weeks. Phase 3 (ATTAIN) reporting through 2026. Hepatic aminotransferase monitoring is being watched.
• CagriSema — REDEFINE-1 phase 3 topline (Garvey, 2024): ~22% at 68 weeks. Approval decisions expected 2026–2027; positioning against tirzepatide is the commercial question.
• Mazdutide (Signifor) — Innovent / Lilly China GLP-1 + glucagon dual agonist. Approved by China NMPA in June 2025 for both obesity and T2D based on GLORY-1 (~14.4% at 48 weeks, 9 mg dose). Lilly holds ex-China rights and is expected to file the FDA NDA in 2027, with a realistic US launch in 2028–2029. No legal US access route exists today; any product sold as “mazdutide” from an overseas or telehealth channel is not the Innovent molecule.
• MariTide (maridebart cafraglutide) — Amgen bispecific GLP-1 agonist + GIP receptor antagonist conjugated to a monoclonal antibody backbone, dosed once monthly. MARITIME-2 Phase 2b (Rosenstock 2025 JAMA, n=592) reported ~19.5% weight loss at 52 weeks on the 420 mg monthly dose, with no plateau at week 52 and a Phase 1b extension signal suggesting partial persistence of weight loss after cessation. Phase 3 MARITIME-1 fully enrolled Q3 2025; topline expected Q4 2026, realistic US availability late 2027 to 2028. The bispecific antibody-peptide conjugate is not accessible to 503A compounding, so no legal or gray-market route exists today — any product sold as “MariTide” or “AMG 133” is mislabeled semaglutide, mislabeled tirzepatide, or an unknown compound.
• VK2735 (Viking Therapeutics) — small-molecule dual GLP-1 / GIP receptor agonist in parallel development as a weekly subcutaneous injection and a daily oral tablet. VENTURE-1 Phase 2 SC topline (Viking, March 2024) reported roughly 14.7% placebo-adjusted weight loss at just 13 weeks at the 5 mg dose — the largest short-window Phase 2 obesity signal reported to date; the 52-week Phase 3 magnitude is genuinely unknown. Phase 3 SC enrolment starts late 2025 into 2026 with a primary readout targeted 2027–2028 and realistic FDA availability of the SC form in 2028–2029; the oral tablet is 2–3 years behind on the same clock. VK2735 is a small-molecule non-peptide, has never been on the FDA drug-shortage list, and has no legitimate compounding pathway — any product sold as “VK2735” in 2026 is mislabeled or counterfeit.

Where each pipeline candidate is likeliest to land in first-line use.

• Retatrutide. Highest ceiling on average weight loss. Likely positioned for patients whose 12-week semaglutide or tirzepatide response is under the STEP-4 threshold, or for adults with severe obesity (BMI ≥40) where the added efficacy matters clinically.
• Retatrutide — CV outcomes. SURPASS-CVOT and TRIUMPH-CVOT will shape whether it displaces tirzepatide as first-line or supplements it.
• Orforglipron. First serious oral small-molecule GLP-1 without an absorption enhancer. Likely first-line for patients who prefer or require oral therapy — injection-averse patients, some occupational categories, and adults in cold-chain-limited access settings. Weight-loss ceiling is below tirzepatide but competitive with semaglutide 2.4 mg. For the full oral-vs-injectable read across the four oral GLP-1s that matter in 2026 (Rybelsus, orforglipron, VK2735 oral, and oral amycretin) — with the SNAC-vs-small-molecule engineering split, the fasting rules, and the 2026 US-shelf reality on one page — see oral GLP-1 medications compared.
• CagriSema. Amylin/GLP-1 combination with a distinct nausea profile from tirzepatide; may become a switch destination for patients who cannot tolerate a co-agonist’s GI burden but need more than semaglutide’s efficacy ceiling.

Insurance and prior-authorization playbook (2026)

Coverage — not efficacy — is the single largest determinant of which anti-obesity drug most adults can actually take. The table below sorts the 2026 landscape into six practical buckets so patients and clinicians can plan around what the plan is likely to say before the prescription is written.

Two 2026 specifics matter for CMS-covered patients. The CMS 2024 final rule on Part D coverage for the SELECT cardiovascular indication expanded the number of Medicare beneficiaries who can access Wegovy without a diabetes diagnosis. And the ongoing Treat and Reduce Obesity Act (TROA) legislative effort to close the statutory Part D exclusion has still not passed as of 2026, so obesity-only coverage under Medicare remains unavailable outside cash pay or CVD/HFpEF carve-outs. For the coverage math beyond the PA form itself — copays, deductibles, and manufacturer stacking — see GLP-1 cost and insurance.

What actually goes in a successful appeals letter. When a plan denies a PA the first pass, the second-pass letter is where most approvals turn. Generic “medically necessary” letters without the four elements below are denied more than 60% of the time in commercial-payer audits.

• Specific ICD-10 comorbidity codes. E66.01 (severe obesity due to excess calories), I10 (essential hypertension), E11.9 (T2D), G47.33 (obstructive sleep apnea), or E78.5 (dyslipidemia) — whichever apply, listed by code rather than in prose.
• Documented lifestyle-intervention history. Dates, program names, weight-loss outcomes, and reasons for discontinuation. A vague “patient has tried diet and exercise” is a denial cue.
• Trial citation for the indication. SELECT (Lincoff, NEJM, 2023) for CVD carve-out; SURMOUNT-1 (Jastreboff, NEJM, 2022) for tirzepatide; STEP-1 (Wilding, NEJM, 2021) for semaglutide; SURMOUNT-4 (Aronne, JAMA, 2024) for the maintenance case.
• Step-therapy rationale (when applicable). Which lower-cost agent was tried or is contraindicated, with dose, duration, and outcome or the specific contraindication reason. “Failed metformin at 2 g/day for 12 weeks with < 2% TBWL” is the level of specificity that reverses denials.

Stacking savings — what the plan and manufacturer will actually allow. For commercially insured patients, Wegovy’s NovoCare Savings Card can drop the copay to $225/month; it does not stack with Medicare, Medicaid, TRICARE, or VA benefits. Zepbound’s LillyDirect single-dose vial program is a separate self-pay channel and is not itself a copay card. GoodRx and other discount cards produce meaningful savings on generic phentermine, generic orlistat, and separated bupropion + naltrexone tablets, but they rarely change GLP-1 pricing in a decisive way because those drugs are still under exclusivity. Manufacturer savings-card lifetime caps (commonly $1,800 to $3,600 per year on GLP-1s) mean a patient starting mid-year may see the copay revert to the plan’s uncapped rate in the following January.

When a step-therapy trial is worth doing on its own merits. Step therapy is often framed as a hurdle to reach a GLP-1, but for a subset of patients the step-therapy drug is genuinely first-line. Documenting a real trial — 12 weeks at target dose, not two weeks of missed pills — creates both a legitimate clinical response and, if it doesn’t work, the strongest possible PA evidence for the GLP-1 that follows.

• Phentermine as legitimate first-line. Cost-constrained adult with normal cardiovascular status, no substance-use history, and a short-term motivation window. $10–$30 per month, and state-by-state duration rules apply.
• Contrave as legitimate first-line. Hedonic or reward-driven eating pattern rather than continuous appetite; no seizure disorder, no chronic opioid therapy, no uncontrolled mood-disorder concerns. Roughly $100–$200/month.
• Qsymia as legitimate first-line. Injection-averse adult with no glaucoma, no hyperthyroidism, and pregnancy potential managed by contraception. Approaches double-digit weight loss on oral therapy. Roughly $200–$250/month.
• Orlistat as legitimate first-line. Adult who cannot use systemic or injectable agents (severe polypharmacy, some transplant patients) and will take a fat-soluble multivitamin two hours off-dose. Modest loss but a real option.
• Off-label metformin as a lifestyle-adjacent adjunct. For adults with prediabetes or PCOS, metformin trial documentation often satisfies step therapy while providing a 2–3% weight loss and glycemic benefit in its own right. Not a substitute for an FDA-approved anti-obesity drug but a defensible pre-step. See metformin and weight.
• Documented failure counts even when informal. A patient log of a real, honest 12-week trial with dose, adherence, side effects, and reason for discontinuation is stronger PA evidence than a partial chart note; commercial payers audit these routinely.

How to have the prescription-medication conversation with your clinician

A 15–20 minute primary-care visit rarely leaves room for a full medication comparison. The five-step protocol below is what obesity-medicine specialists (Endocrine Society 2025 clinical practice guideline; Obesity Medicine Association 2024 position statement) recommend patients bring to the visit so the conversation lands in one appointment instead of three.

For patients whose access route runs through virtual care, the same five steps apply — with an added check that the clinic dispenses through an FDA-registered pharmacy and requires baseline labs before prescribing. See telehealth weight loss for what a legitimate telehealth-clinic intake looks like.

A short pre-visit checklist. Ten minutes of preparation at home moves the conversation from “collect a history” to “choose a drug” inside a single visit. Print and bring:

• Weight log — at least 12 weeks of weekly at-home weigh-ins.
• Current medications — brand and generic names, doses, and how long you have been on each.
• Recent labs — A1C, lipid panel, LFTs (ALT, AST), TSH, and BMP within the last 6 months if possible.
• Home BP readings — at least two weeks of morning/evening measurements if you have a cuff.
• Prior weight-loss attempts — what you tried, how long, and why it stopped (side effects, cost, life event, plateau).
• Family history flags — personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, or seizure disorder.
• Comorbidity list — hypertension, T2D or prediabetes, sleep apnea, PCOS, MASLD, or established CVD.
• Insurance card and PBM name — Caremark, Express Scripts, OptumRx, or other; the clinic can run the benefits check faster with this in hand.

After the visit — what to log in the first 4 weeks. This log is the raw material for the 12-week reassessment and is what turns a “how is it going?” question into an actionable dose or class decision.

• Weight — once weekly at the same time of day, same clothing state.
• Nausea rating (0–10) — daily if starting a GLP-1; note the peak in the 48 hours after each injection.
• GI events — vomiting, constipation, or diarrhea with timing relative to the dose.
• Appetite pattern — meal size, satiety timing, and any food aversions.
• Mood changes — energy, motivation, irritability (especially if starting Contrave).
• Sleep changes — total sleep, awakenings, and time-to-fall-asleep (especially if starting Qsymia or phentermine).
• Cardiovascular signals — home BP, resting HR, and any new palpitations if starting a sympathomimetic.
• Injection-site reactions — redness, swelling, or nodules for injectable GLP-1s.

Two conversations most clinics skip. Both fit inside the initial prescribing visit and prevent an urgent-care call later.

• Sick-day rules. GLP-1s slow gastric emptying, which raises the risk of dehydration during a viral illness with vomiting; the practical rule is to hold the weekly dose until symptoms resolve and hydration is restored. Phentermine and Qsymia should be held during any febrile illness because of BP/HR effects.
• Elective surgery. Anesthesiology societies (ASA 2023 guidance) now recommend holding a GLP-1 for one dose interval before an elective procedure — the aspiration-risk data from delayed gastric emptying has firmed up enough to make this the default. Discuss timing with the surgical team well in advance so the procedure is not rescheduled.
• Contraception counseling. Every FDA-approved anti-obesity drug is contraindicated in pregnancy; some (Qsymia in particular) carry teratogenicity REMS. Contraception counseling is standard-of-care at the initial visit for any adult of reproductive potential.
• Alcohol. Alcohol adds calories, worsens sleep, and — on GLP-1s — can amplify nausea; on Contrave it interacts with bupropion’s seizure-threshold effect. A specific drink-count guidance in the first visit reduces GI-related discontinuation.
• Injection technique for GLP-1 starters. A single 5-minute demonstration of pen priming, injection-site rotation (abdomen, thigh, upper arm), and post-injection storage prevents a large share of first-week discontinuations.
• What to do if a dose is missed. GLP-1 weekly dosing tolerates a missed dose within 48 hours; beyond that, resume the schedule and skip the missed dose. Documenting this in writing at the initial visit is what prevents a mid-week emergency call.
• Home-BP cadence for sympathomimetics. For phentermine or Qsymia starters, twice-weekly morning BP checks for the first month, then weekly, until the response is stable. Bring the log to the 4-week visit.
• Vitamin repletion for orlistat. A daily fat-soluble multivitamin (A, D, E, K) taken 2 hours off the orlistat dose is not optional; without it, subclinical deficiency is common by 6 months.
• Pharmacy of record. For any injectable GLP-1, confirm the dispensing pharmacy is FDA-registered and that refills are on a stable cadence; supply disruptions were common in 2023–2024 and still occur.

Off-label combinations and adjuncts — what actually gets used and what to know

Community and specialist clinicians sometimes combine anti-obesity drugs, or add adjunctive medications not FDA-approved for weight loss, to address a plateau, a comorbidity, or a specific patient constraint. None of the combinations below is an FDA-approved obesity combination; each carries a specific evidence base and safety flag. Anything on this list is a conversation with a prescribing clinician, not a self-prescribing protocol.

These are not FDA-approved combinations. Every entry above requires a prescribing clinician who is monitoring for the specific safety signal listed, and (in most cases) a documented failure of monotherapy at maximum tolerated dose before the combination is tried.

General principles for thinking about combinations. Three rules keep an off-label combination on the safe side of clinical reasoning.

• Maximize monotherapy first. No combination should be tried before the first-line drug has been titrated to maximum tolerated dose and re-checked at 12 weeks — most “non-responders” are actually under-titrated. AACE 2023 and Endocrine Society 2025 guidelines both anchor this.
• Distinct mechanism, not additive dose. The second drug should hit a different pathway from the first — sympathomimetic added to appetite suppression, insulin sensitization added to appetite suppression, or amylin added to incretin — rather than two drugs in the same class stacked.
• Additive monitoring, not shared monitoring. A GLP-1 + phentermine combination requires both the GLP-1’s pancreatic-lipase and thyroid monitoring and the phentermine’s blood-pressure and heart-rate monitoring, not one or the other. Every safety signal from each contributing monotherapy is still live.
• Documented rationale in the chart. Off-label combinations are audit-visible; a chart note describing why monotherapy failed, why the second drug was chosen, and what monitoring cadence was set is what protects both patient and prescriber if a payer or state board reviews the record later.

When to stop, switch, or dose-escalate — a 5-row decision matrix

The decision to continue, change, or stop an anti-obesity medication is a set of clinical inflection points, not a single stop-date. The matrix below aligns 2026 practice with the STEP-4 responder criterion (Rubino, JAMA, 2021), the SURMOUNT-4 maintenance data (Aronne, JAMA, 2024), and the Endocrine Society 2025 clinical practice guideline.

The matrix has a shared principle: response is defined against maximum tolerated dose, not starting dose, and always at a specific week. Skipping the 12-week check risks continuing a non-responder on an expensive drug; skipping the 24-week plateau assessment risks reflexive dose-escalation into intolerance. Both are common and both are avoidable.

Class-specific washout timelines for pregnancy planning. See weight loss after pregnancy for post-partum re-initiation and breastfeeding-compatible options.

• Semaglutide — at least 8 weeks off before attempting conception (five drug half-lives at t½ ≈ 7 days).
• Tirzepatide — at least 4 weeks off before attempting conception (t½ ≈ 5 days).
• Liraglutide — 2 weeks off (t½ ≈ 13 hours).
• Naltrexone-bupropion — 2 weeks off; bupropion carries a Category C pregnancy classification under the old system.
• Phentermine and Qsymia — stop before attempting conception; Qsymia carries a teratogenicity REMS requiring monthly pregnancy tests for women of reproductive potential.
• Orlistat — stop before attempting conception; not recommended in pregnancy despite minimal systemic absorption because of fat-soluble vitamin depletion risk.
• Setmelanotide — stop before attempting conception; pregnancy-safety data are limited.

How to time the check-ins so they land. This cadence maps cleanly to the PA re-authorization schedule most commercial plans use (12 weeks initial, 24 weeks first renewal, then annually) — the visit data and the plan data support each other rather than working on parallel timelines.

• Week 4 — tolerance check, dose-escalation logistics, and troubleshooting titration-related side effects.
• Week 12 — STEP-4 responder criterion at maximum tolerated dose (Rubino, JAMA, 2021); go/no-go decision on continuing the current class.
• Week 24 — plateau assessment, lean-mass preservation review, and lifestyle intensification (protein target, resistance training frequency, sleep).
• Weeks 36, 48, 60 — quarterly maintenance visits through the first year with weight, side-effect log, and any labs the drug class calls for.
• Year 2 and beyond — twice-yearly visits, aligned with annual PA renewal and cardiometabolic labs (A1C, lipid panel, LFTs).

What a switch actually looks like on the calendar. Documenting the switch date and rationale in the chart is what a follow-up PA form will ask for.

• Semaglutide → tirzepatide. Accept the natural taper of the missed weekly semaglutide dose while tirzepatide titrates in; start tirzepatide at 2.5 mg and follow the standard four-week titration schedule to the target dose. Typical time to a decision on the new drug: 12–16 weeks.
• Tirzepatide → semaglutide. The reverse is uncommon; usually only done for a payer-driven switch or a tirzepatide-specific side effect. Start at 0.25 mg and titrate weekly per the standard STEP schedule.
• GLP-1 → Qsymia. Allow 4 weeks off the GLP-1 so residual anti-emetic effects clear and any Qsymia-specific paresthesia, taste change, or cognitive fog is not conflated with GLP-1 recovery. Start at 3.75/23 mg and follow the two-week titration to 7.5/46 mg with a 12-week response check.
• GLP-1 → phentermine. Confirm a normal cardiovascular baseline (BP < 140/90, resting HR < 90) before starting; short-term duration limits apply in most states.
• Any class → withdrawal. Taper where possible over 8–12 weeks; schedule 4-, 12-, and 24-week weight checks; protect protein intake at ≥1.6 g/kg/day and continue resistance training. Rebound is fastest in the first 12 weeks after withdrawal (Wilding STEP-1 extension, 2022).

Combining medications with lifestyle

Pharmacotherapy multiplies the effect of lifestyle change; it does not replace it.

• Behavioral therapy plus medication. Wadden 2011 (NEJM) showed intensive behavioral therapy plus sibutramine produced meaningfully more weight loss than either alone — a pattern that generalizes to current agents. Modern trials of semaglutide and tirzepatide are conducted on top of a lifestyle-intervention background for the same reason.
• Protein and resistance training. Rapid weight loss (>1.5% per week on any modality) accelerates lean-mass loss unless protein intake (approximately 1.6 g/kg/day) and resistance training at least twice weekly are protected. This is a routine deficit on GLP-1s at maximum doses.
• Sleep and stress. Sleep restriction and chronic stress raise appetite and reduce adherence to any regimen. Simple sleep-hygiene and stress-management guidance is a low-cost adjunct that many clinical pathways skip.
• Alcohol. Alcohol adds calories, worsens sleep, and, on GLP-1s, can amplify nausea; on Contrave, it interacts with bupropion’s seizure-threshold effect and adds naltrexone-mediated changes in perception of intoxication.

When medications aren’t right

Pharmacotherapy is not the answer for every eligible adult.

• Pregnancy, planned pregnancy, or breastfeeding. All FDA-approved anti-obesity drugs are contraindicated. GLP-1s require at least a two-month washout before conception because of their long half-life.
• History of pancreatitis. Relative contraindication for GLP-1s; another class is usually preferred first.
• Uncontrolled hypertension or established cardiovascular disease. Phentermine and Qsymia are avoided; a GLP-1 (which usually lowers BP) is generally preferred. See our companion piece on the safety profile comparison across classes.
• MEN2 syndrome or personal/family history of medullary thyroid carcinoma. Absolute contraindication for all GLP-1 agonists.
• Active eating disorder. Stimulants and appetite-suppressing agents can worsen restrictive behaviors; an eating-disorder team should be in the prescribing loop.
• Chronic opioid therapy. Contrave is contraindicated because naltrexone precipitates withdrawal.
• Seizure disorder. Contrave is contraindicated; bupropion lowers the seizure threshold.

What’s coming next

Four late-stage or recently launched developments are changing the shape of this list.

• Retatrutide (GIP + GLP-1 + glucagon triple agonist). Phase 2 trials showed ~24% mean weight loss at 48 weeks; SURPASS-CVOT and the TRIUMPH obesity program are running. If approved, it would move the ceiling above tirzepatide.
• Oral GLP-1s. Oral semaglutide (Rybelsus) is approved for type 2 diabetes and is under active study at higher doses (25 mg, 50 mg) for obesity. Danuglipron (Pfizer) has faced tolerability challenges but the small-molecule oral GLP-1 category is progressing.
• CagriSema (cagrilintide + semaglutide). A weekly amylin/GLP-1 combination in phase 3 that produced roughly 22% weight loss at 68 weeks in REDEFINE-1; approval decisions are expected in 2026–2027.
• Amycretin (single-molecule amylin + GLP-1 co-agonist). Novo Nordisk’s Phase 2 candidate — the only single-molecule amylin/GLP-1 drug in development — is being developed in parallel as a weekly subcutaneous injection and a daily oral tablet. Phase 1b showed ~13.1% weight loss at 20 weeks (SC, Frías 2024) and ~13.1% at 12 weeks (oral, Rosenstock 2025 Lancet); Phase 2 readouts land 2027 and realistic US availability is 2030 at the earliest.
• Petrelintide (ZP8396) (long-acting amylin monotherapy). Zealand Pharma’s Phase 2 candidate is the only amylin-only drug in active obesity development globally in 2026 — no GLP-1 component. Phase 1b showed a dose-response from ~5% to ~8.6% weight loss at 16 weeks with a nausea profile roughly half that of early-titration semaglutide. Positioned as the “amylin without the GLP-1” alternative for patients who cannot tolerate the GLP-1 class; realistic US availability is 2029–2030.
• Survodutide (GLP-1 + glucagon dual agonist). Boehringer Ingelheim and Zealand Pharma’s Phase 3 candidate produced ~18.7% weight loss at 46 weeks in Le Roux 2024 (Lancet) and became the first drug in its class to receive FDA Breakthrough Therapy Designation for MASH with F2 or F3 fibrosis (February 2024).
• Pemvidutide (ALT-801) (GLP-1 + glucagon dual agonist). Altimmune’s Phase 2 candidate reported ~15.6% placebo-adjusted weight loss at 48 weeks at the 2.4 mg dose in IMPACT Phase 2, plus a distinctive LDL, ApoB, and triglyceride reduction that separates it from the rest of the GLP-1 / glucagon dual class. A parallel Phase 2b MASH biopsy program reads out in 2026; realistic US availability is 2029–2030.
• Adjacent uses. Resmetirom for metabolic dysfunction-associated steatohepatitis (MASH) is not a weight-loss drug but is reshaping the metabolic-disease landscape adults with obesity are moving through.

Bottom line

The 2026 shortlist for prescription weight loss is short, and the choice is usually filtered by cost and coverage before it reaches efficacy. When access exists, tirzepatide or semaglutide is first line for most eligible adults; when it does not, generic phentermine, Contrave, and orlistat still produce meaningful loss for the right patient. Treat any prescription as part of a chronic-care plan with a 12-week response check, not a short-term fix.

Sources at a glance

• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM, 2021.
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022.
• Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). NEJM, 2015.
• Gadde KM et al. Effects of low-dose, controlled-release phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). Lancet, 2011.
• Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet, 2010.
• Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS). Diabetes Care, 2004.
• Clément K et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency (IMCIVREE-201). Lancet Diabetes & Endocrinology, 2020.
• Garvey WT et al. AACE 2023 clinical practice guideline on the pharmacological management of adults with obesity.
• Watanabe JH et al. Real-world weight loss with GLP-1 receptor agonists for chronic weight management, 2024.

How this compares to other options

• Compared with GLP-1 weight loss medications as a category, this hub covers every FDA-approved anti-obesity option — GLP-1s plus the older classes — side by side.
• Compared with bariatric surgery, medications are reversible and lower risk but generally yield smaller average weight change; see bariatric surgery vs GLP-1 medications for a direct head-to-head.
• For access outside the traditional in-person clinic, review telehealth prescribing paths — legitimate telehealth clinics require baseline labs, physician review, and FDA-registered pharmacy dispensing.
• For a closer look at the most-discussed GLP-1 brand, see Ozempic for weight loss.
• For the four-way head-to-head across Ozempic, Wegovy, Mounjaro, and Zepbound, see GLP-1 medications compared.